ClinicalTrials.gg
Status unknownNCT00877409ACNASEUpdated Apr 7, 2009

Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II

A Phase 3 interventional study of Benzoyl Peroxide 5% and Sulphur 2% and Vehicle of Acnase in Acne Vulgaris, sponsored by Zurita Laboratorio Farmaceutico Ltda.. Status unknown at 1 site in Brazil. Open to participants aged 12 Years to 35 Years. Per ClinicalTrials.gov, last updated 2009-04-07.

Sponsored by Zurita Laboratorio Farmaceutico Ltda. · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2009), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
12 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.

Planned enrollment
18th of 33
80 · median 90
Started
2009
with 5 others
Phase 3
11 of 33
none open now
Registered
11th of 33
by date
Lead sponsor
2 of 33
Zurita Laboratorio Farmaceutico Ltda.

Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 18th largest by planned enrollment, is one of 6 that started in 2009, is one of 11 in phase 3, and was the 11th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About Benzoyl Peroxide

Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 12 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies testing Benzoyl Peroxide in Acne Vulgaris as a file.
02

Study summary

The objective of this study is to establish the safety in use of the topical drug Acnase Creme and its effectiveness in treatment of acne grade I (comedones) and II (comedones, papules, pustules).

Read the detailed description

The acne is a common dermatosis in dermatological practice, affects more than 80% of the population during the second and third decades of life. It is found worldwide, with no evidence of racial or ethnic differences that influence the susceptibility to its development. However there is influence of genetic factors, hormones, the use of certain drugs that may have previous or aggravate the disease.

It is an inflammatory disease of the follicle polissebáceo, which consists of large sebaceous glands, multiacinares, rudimentary hair follicle and a channel comprising a acro-infundibulum in its upper portion and an infra-infundibulum in the dermal portion.

This is a benign condition, self-limited, but can cause serious psychological problems or disfiguring scars, which can persist for the rest of life.

The initial change is a disorder of follicular epithelial differentiation, during which the cornea cells (keratinocytes) which are the follicle polissebáceo are excessively released in the lumen. The result of this event is the appearance of the precursor, microcomedão, from which the lesions of acne are developed (closed comedones, open comedones, papules, pustules and nodules). The dilation of the follicular infundibulum with the material produces a corneal comedão closed. This is the first clinically visible lesions of acne. As hyperkeratosis extends to the upper infundibulum, extended its opening, it formed the comedão open.

The pathogenesis of acne is complex and understood only in part. The follicular occlusion with adherent keratinocytes and activation of hormone secretion resulting in the formation of sebaceous microcomedão. Studies suggest that free fatty acids intrafoliculares control inflammation through chemotactic properties on leukocytes, monocytes and neutrophils. The free fatty acids may provide the primary stimulus for the retention hyperkeratosis follicularis. Moreover, tallow provides a favorable substrate for the proliferation of Propiniobacterium acnes (P. acnes). Studies suggest that P. acnes, a microaerophilic bacterium (almost anaerobic), Gram-positive, has a lipase able to hydrolyze triglycerides in sebum into free fatty acids. Therefore, these pathogens play critical role in the generation of inflammatory lesions. The P. acnes produces proteases and neuroaminidases, which may increase the permeability of the follicular epithelium. Also produce a chemotactic factor of low molecular weight that selects the polymorphonuclear leukocytes. In the process of phagocytosis of bacteria are released hydrolases, which break the integrity of the follicular wall. Subsequently, the content intrafolicular - fragments of keratin, fat, hair, and P. acnes - is expelled to the dermis.

If surface aggregation of neutrophils, as was a wheal, and with the presence of purulent secretion, a pustule. With the infiltration of inflammation deep and extensive, a nodule or cyst is produced.

Clinically, the eruption acnéica is located predominantly in the face (90%) and to a lesser extent, in the back (60%) and chest (15%). As young man, mainly affects the face, while in older, the back.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acnase
  • Acne Vulgaris
  • Safety
  • Efficacy
04

Who can participate

Ages eligible
12 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 12 to 35 years;
  • Oily skin with tendency to acne;
  • Presence of non-inflammatory lesions and inflammatory, acne vulgaris diagnosed as grade I or II, as the following: I) Comedones - only comedones; II) Papulopustular - comedones, papules and pustules; III) Nodulocystic - comedones, papules, pustules, nodules and cysts; IV) Conglobates - severe acne, usually affects other areas of the body, out of preference, giving comedones, papules, pustules, abscesses, confluent nodules, cysts and scars.
  • Agreement in compliance with the procedures of the trial and attend the clinic on certain days and times for medical evaluations and scores of injuries acne;
  • Signing of the Term of Free and and agreement of the lowest in the case of patients between 12 and 17 years.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy (pregnancy test by urinary indication to women voluntary of childbearing age);
  • Nursing;
  • Nodulocystic and Conglobates acne;
  • Conditions associated hormone (tireoid disease, micropolicysts ovaries, adrenal or pituitary disorders);
  • Drug use systemic , anticonvulsants, photo-sensibility and / or new drugs for up to 01 months before the selection;
  • Use of topical therapy, systemic or physical (cleaning of the skin) for the treatment of acne at least 01 months before the selection;
  • History of atopic or allergic skin;
  • History of to Benzoyl peroxide or sulfur;
  • Skin Conditions active (and / or spread) that may interfere with the outcome of the study;
  • Beginning or end-use of ; (for females)
  • Sunlight intense exposure until 01 months before the assessment;
  • Aesthetic treatments, skin up to 01 months before the selection;
  • Use of specific oily cosmetic for skin / acne and makeup, facial moisturizing, etc..;
  • Use of the drug Acnase prior to inclusion in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Acnase

    Drug: Benzoyl Peroxide 5% and Sulphur 2%

  • Placebo comparator
    Vehicle

    Drug: Vehicle of Acnase

Interventions

  • DrugBenzoyl Peroxide 5% and Sulphur 2%

    Drug page: Benzoyl Peroxide

    The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.

    Also known as: Acnase

  • DrugVehicle of Acnase

    The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.

    Also known as: Control, Vehicle, Placebo

06

What researchers measure

Primary outcomes

  1. Average clinical development of target lesions of the groups for each experimental time.

    Time frame: 12 weeks

Secondary outcomes

  1. Clinical evolution of the acne through the counting of inflammatory and non - inflammatory lesions.

    Time frame: 12 weeks

  2. Evaluation of oily skin through the clinical evaluation with four-point scale (absent, mild, moderate, intense)

    Time frame: 12 weeks

  3. Observation of occurrence and intensity of clinical parameters erythema, scaling, itching and burning through the clinical evaluation with four-point scale (absent, mild, moderate, severe).

    Time frame: 12 weeks

07

Study locations

1 site
  • Medcin Instituto da Pele Ltda.
    Osasco, São Paulo 06023-000, Brazil
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2009
First posted
Apr 7, 2009
Start
Apr 2009
Primary completionEst.
Jul 2009
CompletionEst.
Jul 2009
Last update
Apr 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00877409
Lead sponsor
Zurita Laboratorio Farmaceutico Ltda.
First posted
Apr 7, 2009
Start date
Apr 2009
Primary completion
Jul 2009 (estimated)
Completion
Jul 2009 (estimated)
Last update
Apr 7, 2009

Study contacts

Sergio Schalka, MD
Contact
sergio@medcinonline.com.br
55-11-36546362
Sérgio Schalka, MD
principal investigator · Medcin Instituto da Pele Ltda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benzoyl Peroxide

Start the discussion